Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02908464 · ClinicalTrials.gov registry record · NA

Prevention of Early Postoperative Decline

A NA study of Delirium and Postoperative Cognitive Dysfunction, sponsored by Beth Israel Deaconess Medical Center.

Completed
Registry status
NA
Development phase
45
Enrollment target
1
Study location

NCT02908464: Completed NA study of Delirium and Postoperative Cognitive Dysfunction, sponsored by Beth Israel Deaconess Medical Center.

NCT02908464 is a NA study of Delirium and Postoperative Cognitive Dysfunction that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 45 participants, below the 887-participant average among 62 other Delirium trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02908464, a NA study of Delirium and Postoperative Cognitive Dysfunction, has completed, sponsored by Beth Israel Deaconess Medical Center.

COMPLETED
Registry status
NA
Development phase
45 participants
Enrollment target
1
Study location

Study Summary

The purpose of this trial is to determine whether using a brain training program in the time leading up to as well as after heart surgery will reduce confusion and cognitive loss that can occur after surgery.

Primary Outcome

Feasibility will be partly determined by evaluating enrollment. Enrolling \>50% of eligible patients is the target.

Interventions

  • DEVICE Lumosity

Study Locations (1)

Massachusetts

  • Beth Israel Deaconess Medical Center - Boston

Trial Details

FieldValue
Enrollment Target 45 participants
Start Date 2016-11
Est. Completion 2019-09
Phase NA

What the finished NCT02908464 record still lists

NCT02908464 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 887-participant average among 62 other Delirium trials with a reported enrollment target (95% lower).

The record links to 2 conditions, with Delirium appearing as the primary indexed condition, and to 1 intervention - of which Lumosity is the first listed.

NCT02908464 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT02908464 about?

NCT02908464 is a clinical study titled "Prevention of Early Postoperative Decline". The purpose of this trial is to determine whether using a brain training program in the time leading up to as well as after heart surgery will reduce confusion and cognitive loss that can occur after surgery.

What is the current status of trial NCT02908464?

This trial is currently completed. It is a NA study. The enrollment target is 45 participants. The study started on 2016-11. Estimated completion is 2019-09.

What conditions does trial NCT02908464 study?

This clinical trial studies the following conditions: Delirium, Postoperative Cognitive Dysfunction.

What interventions are being tested in trial NCT02908464?

The interventions under investigation include: Lumosity (DEVICE).

Who is sponsoring clinical trial NCT02908464?

This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02908464 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Delirium

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02908464's enrollment target sits among peer trials

45 53rd of 62 higher than 10 of 62 other Delirium trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Delirium trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00804154 · 45 participants · Phase 1

    Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer

  • NCT01851694 · 45 participants · NA

    Beta-cell Response to Incretin Hormones in Cystic Fibrosis

  • NCT02896335 · 45 participants · Phase 2

    Palbociclib and Pembrolizumab In Central Nervous System Metastases

  • NCT03454035 · 45 participants · Phase 1

    Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02908464, the US trial registry maintained by the National Library of Medicine. NCT02908464 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.